AGENNIX AG

EANS-News: Agennix AG Schedules Conference Call on July 31 to Discuss Second Quarter 2012 Financial Results

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information


Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 25, 2012 (euro
adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) announced today that the
Company will host a conference call to discuss financial results for the second
quarter and first half of 2012 and to provide a business update. The results
will be published on Tuesday, July 31, 2012, in advance of the conference call. 

The conference call, which will be conducted in English, will be held on
Tuesday, July 31, 2012 at 9 AM ET/3 PM CET.

A live webcast will be available on the Agennix Web site at www.agennix.com. A
replay will be available via the Web site following the live event. 

Dial-in numbers for the call are as follows:

Participants from Europe:       0049 (0)69 7104 45598
                                0044 (0)20 3003 2666
Participants from the U.S.:     1 212 999 6659


Please dial in 10 minutes before the beginning of the conference call.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially lengthen
and improve the lives of critically ill patients in areas of major unmet medical
need. The Company's most advanced investigational agent is talactoferrin alfa, a
first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI). Talactoferrin
alfa is currently in Phase III clinical trials in non-small cell lung cancer.
Other clinical development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing for cancer, and a topical gel form of talactoferrin
for diabetic foot ulcers.  Agennix's registered seat is in Heidelberg, Germany.
The Company has three sites of operation: Planegg/Munich, Germany; Princeton,
New Jersey and Houston, Texas. For additional information, please visit the
Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from those
expressed or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution investors not
to place undue reliance on the forward-looking statements contained in this
press release. The achievement of positive results in early stage clinical
studies does not ensure that later stage or large scale clinical studies will be
successful.  Even if the results from our later stage trials with talactoferrin,
including the ongoing FORTIS-M trial in non-small cell lung cancer, are
considered positive, there can be no guarantee that they will be sufficient to
gain marketing approval in the United States or any other country, and
regulatory authorities may require additional information, data and/or further
pre-clinical or clinical studies to support approval.  In such event, there can
be no guarantee that the Company will have or be able to obtain the financial
resources to conduct any such additional studies or that such studies will yield
results sufficient for approval. Even if the results from the FORTIS-M trial are
considered positive, there can be no guarantee that the Company will be able to
partner talactoferrin or obtain additional financial resources.  Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.

Agennix® is a trademark of Agennix AG.


Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications 
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884 
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Senior Vice President
Phone: +44 207 936 9325 
lwilliams@troutgroup.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
mail:     ir@agennix.com
WWW:      http://www.agennix.com
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             regulated dealing/prime standard: Frankfurt 
language:   English
 



Weitere Meldungen: AGENNIX AG

Das könnte Sie auch interessieren: